Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Koninklijke Philips N.V. (PHG)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
21.17+0.18 (+0.86%)
At close: 04:00PM EDT
21.15 +0.01 (+0.05%)
After hours: 04:02PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close20.99
Open21.13
Bid20.66 x 1800
Ask21.50 x 1300
Day's Range20.98 - 21.24
52 Week Range20.20 - 48.72
Volume1,136,221
Avg. Volume2,064,716
Market Cap18.671B
Beta (5Y Monthly)0.81
PE Ratio (TTM)4.54
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.96 (3.96%)
Ex-Dividend DateMay 12, 2022
1y Target EstN/A
  • GlobeNewswire

    Philips completes cancellation of 8.8 million shares

    July 4, 2022Amsterdam, the Netherlands – Royal Philips (NYSE: PHG; AEX: PHIA) today announced that it has completed the cancellation of 8,758,455 of its shares. The cancelled shares were acquired as part of the EUR 1.5 billion share repurchase program for capital reduction purposes that was announced on July 26, 2021.Philips’ current issued share capital amounts to EUR 177,863,016.40 representing 889,315,082 common shares. As communicated earlier, Philips intends to have 19,571,218 shares delive

  • Business Wire

    Philips Signs Health Care Sector Pledge to Reduce Emissions as part of Department of Health and Human Services, White House Initiative

    CAMBRIDGE, Mass., July 01, 2022--Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the company has joined an initiative created by the Department of Health and Human Services (HHS), in partnership with the White House, to address climate action through the reduction of greenhouse gas emissions. Earlier this week at the White House, Philips along with other health sector organizations and administration leaders, participated in a roundtable discussion abo

  • GlobeNewswire

    Philips incorporates Biodesix blood-based proteomic nodule risk assessment testing into Lung Cancer Orchestrator to advance early lung cancer diagnosis

    Lung Cancer Orchestrator June 30, 2022Solution adds proteomic analysis of blood-based biomarkers to Philips Lung Cancer Orchestrator to better assess the risk of lung nodule malignancy, enhancing decision-making for diagnosis and treatment Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has teamed up with Biodesix, Inc. (Colorado, U.S.) (Nasdaq: BDSX), a leading data-driven diagnostic solutions company, to incorporate th

Advertisement
Advertisement